Abrogating Metastatic Properties of Triple-Negative Breast Cancer Cells by EGFR and PI3K Dual Inhibitors
Open Access
Abstract
Triple-negative breast cancer (TNBC) is a devastating BC subtype. Its aggressiveness, allied to the lack of well-defined molecular targets, usually culminates in the appearance of metastases that account for poor prognosis, particularly when they develop in the brain. Nevertheless, TNBC has been associated with epidermal growth factor receptor (EGFR) overexpression, leading to downstream phosphoinositide 3-kinase (PI3K) signaling activation. We aimed to unravel novel drug candidates for TNBC treatment based on EGFR and/or PI3K inhibition. Using a highly metastatic TNBC cell line with brain tropism (MDA-MB-231 Br4) and a library of 27 drug candidates in silico predicted to inhibit EGFR, PI3K, or EGFR plus PI3K, and to cross the blood–brain barrier, we evaluated the effects on cell viability. The half maximal inhibitory concentration (IC50) of the most cytotoxic ones was established, and cell cycle and death, as well as migration and EGFR pathway intervenient, were further evaluated. Two dual inhibitors emerged as the most promising drugs, with the ability to modulate cell cycle, death, migration and proliferation, morphology, and PI3K/AKT cascade players such as myocyte enhancer factor 2C (MEF2C) and forkhead box P1 (FOXP1). This work revealed EGFR/PI3K dual inhibitors as strong candidates to tackle brain metastatic TNBC cells.Keywords
Funding Information
- Portuguese Foundation for Science and Technology (FCT), Portugal (PTDC/MED-ONC/29402/2017, UIDB/04138/2020, UIDP/04138/2020, 2020.07115.BD)
- FCT (PTDC/MED-ONC/29402/2017, UIDB/04138/2020, UIDP/04138/2020, 2020.07115.BD)
This publication has 78 references indexed in Scilit:
- Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathwaysChemico-Biological Interactions, 2013
- Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosisBreast Cancer Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortalityInternational Journal of Cancer, 2009
- Potentially oncogenic B-cell activation–induced smaller isoforms of FOXP1 are highly expressed in the activated B cell–like subtype of DLBCLBlood, 2008
- Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patientsBritish Journal of Cancer, 2007
- Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell lineApoptosis, 2005
- A small molecule–kinase interaction map for clinical kinase inhibitorsNature Biotechnology, 2005
- CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancerSeminars in Oncology, 2003
- The Phosphoinositide 3-Kinase PathwayScience, 2002